Exhibition cabinet photo
Owlstone Medical logo

Breath Biopsy

Owlstone Medical Closes $58 Million USD (c. £42 Million GBP) Oversubscribed Financing Round to Continue to Advance Breath Biopsy

Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, today announced the close of its Series D financing round, securing $58 million and bringing the total raised by the company to over $150 million since founding in 2016.

07 Sep 21

Owlstone newsletter CTA

Talk to us about your biomarker research and how Breath Biopsy could help.

Contact Us